<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Desloratadine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Desloratadine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Desloratadine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8472" href="/d/html/8472.html" rel="external">see "Desloratadine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12360" href="/d/html/12360.html" rel="external">see "Desloratadine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F157702"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Clarinex</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1057735"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihistamine</span></li></ul></div>
<div class="block dop drugH1Div" id="F157720"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5c8123d5-63e1-4fd0-b4d4-fd52eac80de3">Allergic rhinitis, perennial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, perennial:</b> Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 6 to ≤11 months: 1 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≤5 years: 1.25 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to ≤11 years: 2.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: 5 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="493236ef-6c7e-43e1-b6af-a9ef049ee9c4">Allergic rhinitis, seasonal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, s</b>
<b>easonal:</b> Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to ≤5 years: 1.25 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to ≤11 years: 2.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: 5 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0efe1f7-72dc-4f3b-ae0a-fd400e6c652a">Urticaria, chronic idiopathic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, chronic idiopathic:</b> Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants 6 to ≤11 months: 1 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≤5 years: 1.25 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to ≤11 years: 2.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: 5 mg once daily.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51093611"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling for pediatric patients (has not been studied); based on adult information, dosage adjustment may be necessary.</p></div>
<div class="block dohp drugH1Div" id="F51093612"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling for pediatric patients (has not been studied); based on adult information, dosage adjustment may be necessary.</p></div>
<div class="block doa drugH1Div" id="F157705"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8472" href="/d/html/8472.html" rel="external">see "Desloratadine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed30d02d-dd05-494e-bc5b-0d0387493686">Allergic rhinitis, perennial or seasonal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic rhinitis, perennial or seasonal:</b>
<b>Oral:</b> 5 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="efde08fa-6871-4b29-baeb-2d79f4a232f3">Angioedema, acute allergic or recurrent idiopathic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angioedema, acute allergic or recurrent idiopathic (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not indicated for angioedema associated with anaphylaxis; use epinephrine if anaphylaxis symptoms are present (ie, risk of airway or cardiovascular compromise) (James 2017; Zuraw 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 5 mg once or twice daily; may increase up to 10 mg twice daily (Cicardi 2014; James 2017; Zuraw 2022).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f65880a4-134b-4d60-99af-28a6f3dd6eaa">Urticaria, new onset and chronic spontaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, new onset (off-label use) and chronic spontaneous (labeled use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>New onset:</b>
<b>Oral:</b> Initial: 5 mg once daily. If symptom control is inadequate, may immediately increase to 5 mg twice daily (Asero 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic spontaneous:</b>
<b>Oral:</b> Initial: 5 mg once daily. If symptom control is inadequate, may increase in 5 mg/day increments every 1 to 4 weeks up to 10 mg twice daily; periodically reevaluate necessity for continued treatment (EAACI [Zuberbier 2018]; Khan 2021; Staevska 2010).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea3a9ca5-6597-444d-b063-4c5fdbfb80f2">Urticaria, nonsteroidal anti-inflammatory drug associated, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, nonsteroidal anti-inflammatory drug associated, prophylaxis (off-label use): Oral:</b> 5 mg 30 minutes before intake of a strong COX-1 inhibitor (Trautmann 2016).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991217"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment: No dosage adjustment necessary; use with caution in severe impairment. Although the US manufacturer’s labeling recommends a dose reduction to 5 mg every other day in patients with mild to severe renal impairment, the increased exposure (C<sub>max</sub> and AUC) observed in single- and multiple-dose pharmacokinetic studies is not considered clinically relevant (Aerius Canadian product monograph 2019; Aerius Netherlands prescribing information 2018; Geha 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Poorly dialyzable: No dosage adjustment necessary; use with caution. Although the US manufacturer’s labeling recommends a dose reduction to 5 mg every other day in patients on dialysis, the increased exposure (C<sub>max</sub> and AUC) observed in single- and multiple-dose pharmacokinetic studies is not considered clinically relevant (Aerius Canadian product monograph 2019; Aerius Netherlands prescribing information 2018; Geha 2001).</p></div>
<div class="block doha drugH1Div" id="F50988425"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary; use with caution in severe impairment. Although the US manufacturer’s labeling recommends a dose reduction to 5 mg every other day in patients with mild to severe hepatic impairment, the increased exposure (C<sub>max</sub> and AUC) observed in single- and multiple-dose pharmacokinetic studies is not considered clinically relevant (Aerius Canadian product monograph 2019; Geha 2001).</p></div>
<div class="block adr drugH1Div" id="F157675"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (infants and children: 15% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (14%), irritability (infants: 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (infants and children: 11%), upper respiratory tract infection (infants and children: 11% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (infants and children: 5% to 17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (infants: 3%), maculopapular rash (children: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (infants: 5%), dyspepsia (3%), increased appetite (children: 3%), nausea (infants, children, adolescents, and adults: 3% to 5%), vomiting (infants: 6%), xerostomia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (children: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Parasitic infection (children: 3%), varicella zoster infection (children: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (4%), drowsiness (infants: 9%), emotional lability (children: 3%), fatigue (2% to 5%), insomnia (infants: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (infants: 6%), epistaxis (children: 3%), pharyngitis (infants, children, adolescents, and adults: 3% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Palpitations, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, increased liver enzymes (including increased serum bilirubin)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Movement disorder (including dystonia, extrapyramidal reaction, tic disorder), psychomotor agitation, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p></div>
<div class="block coi drugH1Div" id="F157687"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to desloratadine, loratadine, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F157673"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (including anaphylaxis) have been reported with use; discontinue therapy immediately with signs/symptoms of hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Slow metabolizers: Use with caution in patients known to be slow metabolizers of desloratadine (incidence of side effects may be increased).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Some products may contain phenylalanine.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878411"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;">Desloratadine may increase susceptibility to seizures in pediatric patients, particularly in patients with a history of seizure disorders; 1 case series described 4 patients (ages: 5 to 16 years) who experienced seizures after initiation of desloratadine. 3 of the 4 patients had known seizure disorders that were controlled prior to treatment with desloratadine. The final patient, who developed absence seizures after initiation of desloratadine, had a family history of febrile seizures but no personal history of seizure disorder (Cerminara 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported. Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F157682"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clarinex: 5 mg [contains corn starch, fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clarinex: 5 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg</p></div>
<div class="block geq drugH1Div" id="F157669"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F157689"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Desloratadine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $5.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $5.83</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Clarinex Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $10.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Desloratadine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $5.02 - $8.69</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52612498"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer without regard to food.</p>
<p style="text-indent:-2em;margin-left:2em;">Orally-dissolving tablet: Place orally-dissolving tablet directly on the tongue; tablet will disintegrate immediately; may be taken with or without water. Take immediately after removing from blister package.</p>
<p style="text-indent:-2em;margin-left:2em;">Syrup: A commercially available measuring dropper or syringe calibrated to deliver 2 mL or 2.5 mL should be used to administer appropriate dose.</p></div>
<div class="block adm drugH1Div" id="F157684"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">May be taken with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">Orally disintegrating tablets should be placed on the tongue; tablet will disintegrate immediately. Take immediately after removing from blister package. Allow tablet to dissolve completely before swallowing. May be taken with or without water.</p></div>
<div class="block sts drugH1Div" id="F157698"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Tablet, orally disintegrating: Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 85°F). Protect from moisture and excessive heat. Use orally disintegrating tablet immediately after opening blister package.</p></div>
<div class="block usep drugH1Div" id="F53566395"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Symptomatic relief of nasal and non-nasal symptoms of perennial allergic rhinitis (FDA approved in ages ≥6 months and adults); symptomatic relief of nasal and non-nasal symptoms of seasonal allergic rhinitis (FDA approved in ages ≥2 years and adults); symptomatic relief and reduction in number and size of hives in chronic idiopathic urticaria (FDA approved in ages ≥6 months and adults).</p></div>
<div class="block mst drugH1Div" id="F7258803"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Clarinex may be confused with Celebrex</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9837880"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C8 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F157677"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Moderate): May increase the serum concentration of Desloratadine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Inhibitors (Strong): May increase the serum concentration of Desloratadine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F157699"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food does not affect bioavailability.</p></div>
<div class="block dic drugH1Div" id="F157691"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain phenylalanine.</p></div>
<div class="block pri drugH1Div" id="F157690"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Guidelines for the use of antihistamines in the treatment of allergic rhinitis or urticaria in pregnancy are generally the same as in nonpregnant females. Second generation antihistamines may be used for the treatment of allergic rhinitis and urticaria during pregnancy; however, information related to the use of desloratadine in pregnancy is limited and other medications may be preferred (BSACI [Powell 2015]; BSACI [Scadding 2017]; Zuberbier 2018).</p></div>
<div class="block mopp drugH1Div" id="F53566397"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CNS symptoms including sedation.</p></div>
<div class="block pha drugH1Div" id="F157672"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Desloratadine, a major active metabolite of loratadine, is a long-acting tricyclic antihistamine with selective peripheral histamine H<sub>1</sub>-receptor antagonistic activity.</p></div>
<div class="block phk drugH1Div" id="F157686"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Within 1 hour.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~49 L/kg (Devillier 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Desloratadine: 82% to 87%; 3-hydroxydesloratadine (active metabolite): 85% to 89%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to active metabolite, 3-hydroxydesloratadine (specific enzymes not identified); subsequently undergoes glucuronidation. Decreased in slow metabolizers of desloratadine.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 5 years: Mean: 16.4 hours (Gupta 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 11 years: Mean: 19.4 hours (Gupta 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~27 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 5 years: Mean: 3.17 hours (range: 1.5 to 8 hours) (Gupta 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 11 years: Mean: 3.57 hours (range: 4 to 12 hours) (Gupta 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (41% of radioactive dose); feces (47% of radioactive dose) (Devillier 2008).</p></div>
<div class="block phksp drugH1Div" id="F51220977"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC and C<sub>max</sub> are increased.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC and half-life are increased.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Systemic exposure in children (based on AUC and C<sub>max</sub>) is similar to adults (Gupta 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: C<sub>max</sub> and AUC are 20% higher. The half-life is 33.7 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F157692"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Actilor | Aeriallerg | Aerius | Deslarex | Desloxan | Dora | Glendes | Hisdine | Lorius</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Azomyr | Delorat | Desaler | Deslo | Desloramar | Desloratadina richet | Frenaler | Hexaler | Novo Alerpriv | Predualergin | Sinaler | Teralmina</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Dasselta | Desloraderm | Desloratadin | Desloratadin actavis | Desloratadin Genericon | Desloratadin Pluspharma | Desloratadin ratiopharm | Desloratadin Sandoz | Desloratadin stada | Desloratadine ratiopharm</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apohealth desloratadine | Blooms the chemist desloratadine | Claramax | Desonex | Priceline pharmacy hayfever &amp; allergy relief</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Adlorin | Aloran | Aslor | Clarex | Deen | Delorin | Delosia | Delot | Delotad | Derat | Des | Desatrol | Deslona | Deslor | Deslorin | Deslosil | Desmark | Desmin | Desodin | Desolet | Desotem | Destacin | Destin | Dora | Isodin | Momento | Neocilor | Orinex | Relergy | Sarinex | Sedno</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Desloratadine ab | Desloratadine actavis | Desloratadine Apotex | Desloratadine EG | Desloratadine krka | Desloratadine sandoz | Desloratadine Teva</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Aerius | D lor | Deslatyne | Deslor | Deslora denk | Erlus | Rodera</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Desloratadin Zentiva | Desloratadine alvogen | Desloratadine ratiopharm | Desloratadine sopharma | Desybel | Flynise | Jovesto</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Aleradina | Aloff | Aloff xpe | Aviant | Desalex | Deslin | Deslorana | Desloratadina | Destadin | Esalerg | Histabloc | Leg | Leg odt | Sigmaliv</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Desloratadin actavis | Desloratadin axapharm | Desloratadin helvepharm | Desloratadin Mepha | Desloratadin Sandoz | Desloratadin spirig hc</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Akerol | Allergus | Delevon | Deller | Deslogen | Desloratadine generis | Desloratadine sp | Doxafin | Dyldes | Erlus | Histadius</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Aerius | D histaplus | Despeval | Despex | Lotadin | Mailen | Neo alledryl | Neoclaritine | Rinofilax | Tamides</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Bei xue | Di heng sai | Fu bi ding | Xin min ting</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Alergus | Alertinol | Amerotadina | Cristhaler | Desalex | Desinista | Deslair | Desler | Deslodex | Desloran | Desloratadina | Desloratadina Genfar | Desloratadina La Sante | Desloratadina mk | Desloratamin | Deslorina | Deslosher | Deslotin | Desloweid | Deslox | Desna | Dexio | Expodes | Ezcloren d | Flaxerd | Gamorvan | Globistamin d | Histair | Histaline | Impodina | Inuxgen | Isticol | Lopidex | Lorad | Mailen | Neohysticlar | Newtarpan | Oxiclarine | Prilex | Renilax | Respimar | Riniloran | Rinotadin | Sidres | Sin alergyn | Sinalergyn | Sinnaller | Sinuxgen | Zeraller</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Azomyr | Dasmini | Dasselta | Delesit | Desloratadin +pharma | Desloratadin apotex | Desloratadin aurovitas | Desloratadin krka | Desloratadin mylan | Desloratadin stada | Desloratadin xantis | Desloratadin Zentiva | Desloratadine actavis | Desloratadine glenmark | Desloratadine Teva | Geslora | Jovesto | Lotera</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Dasselta | Deslopuren | Deslora 1 a pharma | Deslora denk | Desloraderm | Desloradia | Desloranio | Desloratadin | Desloratadin actavis | Desloratadin adgc | Desloratadin AL | Desloratadin aristo | Desloratadin axunio | Desloratadin glenmark | Desloratadin heumann | Desloratadin Hexal | Desloratadin hormosan | Desloratadin ratiopharm | Desloratadin stada | Desloratadine puren | Desloratadine ratiopharm | Lorano pro</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Alerpred | Desarius | Desloratadina | Desloratadina calox | Desloratadina Sandoz | Despeval | Dexio | Esparflin | Lestacan | Lorax | Maxaire | Novo Alerpriv | Ubrile</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Alertan | Aviant | Azomyr | D histaplus | Delorat | Desler | Desloran | Desloratadina | Desloratadina La Sante | Desloratadina mk | Despex | Dexio | Mailen | Neolarmax | Rinofilax</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Dasergin | Dasselta | Desloratadine sandoz | Desloratadine Zentiva | Yosqiero</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Alergaway | Allergaway | Delarex | Delora stop | Desa | Deslorastamine | Deslorat | Deslorex | Embanodex | Endstamine | Fernilar | Hygi-tadine | Lorafast | Nouvonase | Stimloric | Tendratine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Azomyr | Dasselta | Desloratadina | Desloratadina actavis | Desloratadina almus | Desloratadina alter | Desloratadina apotex | Desloratadina Cinfa | Desloratadina combix | Desloratadina Kern | Desloratadina krka | Desloratadina mabo | Desloratadina Mylan | Desloratadina normon | Desloratadina pensa | Desloratadina pharmagenus | Desloratadina Qualigen | Desloratadina ranbaxy | Desloratadina Sandoz | Desloratadina stada | Desloratadina tarbis | Desloratadina Tecnigen | Desloratadina teva | Desloratadina vir</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Aria des | Deslora denk | Deslorat | Desrinal | Destacure | Eslotin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Caredin | Dasselta | Desloratadin orion | Desloratadin stada | Desloratadine actavis | Desloratadine mylan | Desloratadine ratiopharm | Desloratadine Teva | Deslox | Destamin | Flynise | Kevenix</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Dasselta | Desloratadine actavis | Desloratadine almus | Desloratadine arrow | Desloratadine biogaran | Desloratadine Cristers | Desloratadine EG | Desloratadine evolugen | Desloratadine GNR | Desloratadine krka | Desloratadine mylan | Desloratadine phr | Desloratadine Ranbaxy | Desloratadine sandoz | Desloratadine Teva | Desloratadine vj pharm | Desloratadine Zentiva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Desloratadine Teva | Neoclarityn</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Neoclarityn | Pylodes | Rhinohelp | Rinispes</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Deslorin | Destavell</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Alerdin | Dasselta | Desloratadin actavis | Desloratadine Teva | Deslordis | Escontral</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Alvotadin | Azomyr | Desaero | Desloratadine actavis | Desloratadine mylan | Desloratadine ratiopharm | Desloratadine Stada | Desloratadine Teva | Deslorep | Esradin | Inaller | Lordestin | Lordestin akut</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Aleros | Desdin | Deslotine | Destavell | Eslor</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Dasselta | Deslor | Neoclarityn</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Aerius</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alenix | Alerdain | Alerta d | Allerde | Arolor | D alert | D lorinol | D luracise | D-loratin | Dazit | De argella | Delorta | Deltar | Des-od | Desent | Deslor | Deslotag | Desnova | Desobit | Desogold | Deswin | Dexly | Dezlin | Dezlorid | Disitch | Dyl | Dyl d | Eslot | Isolor | Lorava | Lorday | Loreta | Nelora | Neoloridin | Nucope | Otrivin-alert | Rodera | Sylor | Tastylora</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Awadelor | Desloradain | Deslorasam | Deslorid | Dislorasam | Larius</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Aerius</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Azomyr | Dasselta | Desloratadina | Desloratadina actavis | Desloratadina aurobindo | Desloratadina doc generici | Desloratadina EG | Desloratadina mylan pharma | Desloratadina pensa | Desloratadina ratiopharm | Desloratadina Sandoz | Desloratadina Zentiva | Efestad</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Aeriallerg | Aerius | Ales | Deslora | Dislara | Histacare | Lorius | Noura</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Desalex</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aerius | D lor | D lorat | Dazit | Delora | Desafe | Deselex | Deslatyne | Deslora denk | Deslorin | Deslot | Desodin | Desostar | Doxafin | Larinex | Momento | Neocilor | Neolor</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aerius</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Actilor | Aerius | Iris</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aeriallerg | Aerius | Dareq | Deline | Deslor | Desloratadine arrow | Desloratadine normon | Eslorat | Oradus | Rina</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Dasselta | Desloratadina Kern Pharma | Desloratadine Rph | Desloratadine sopharma | Kevenix | Rodispes | Veromon</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Desloratadine EG</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Dasselta | Desloratadine actavis | Desloratadine aurovitas | Desloratadine sopharma</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Destec | Desyal | Ergic | Erlus | Lodes | Loreus | Naureus</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Abrunt | Aviant | Azomyr | Bennet | Blotamin | Degortrina | Deslibal | Desloratadina | Desloratadina landsteiner | Gronase | Histapharm | Kajuva | Liberdux | Lideater | Lirudine | Selectaler | Sensidex | Tadocil | Urtisin lam | Valgab</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Ajalorin | Avorius | Caridine | Dasselta | Desloratadine sandoz | Deslova | Destacure | Dezal | Glendes | Sedno | Synerrv desloratadine | Xynoz</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Delora stop | Hayvent | Mairex | Momento</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Dasselta | Desloratadine 2,5 mg focus | Desloratadine ratiopharm | Desloratadine Teva | Neoclarityn</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Caredin | Desloratadin glenmark</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Claramax | Hayfever &amp; allergy | Hayfever &amp; allergy relief</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Aviant | D'Ventil | Desloglob | Deslorafen | Desloramina | Desloran | Deslorat | Desloratadina | Deslortin | Frenaler | Letizia | Lomed | Loralergan | Nafolix | Neoclarityne | Neolarmax | New lorat | Rinodual | Rinofilax | Ryna del | Vitallerg</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Allergon | Aroled | Deslo | Deslodine | Deslogen | Deslorastal | Genodes | Neo loridin | Sarinex</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Agenor | Alenor | Alldes | Aloran | Aloret | Altadine | Antimin d | Arozid | D lor | D next | Delergic | Dellerge | Delomat | Delorta | Delorvin | Delot | Deltafast | Des loratlax | Des-od | Desatil | Desbro | Descover | Desdine | Desgen | Deslet | Deslin | Deslo | Deslofn | Deslorat | Deslort | Deslotin | Deslozam | Deslozon | Desmed | Desnova | Deso l | Desora | Desotin | Destazine | Destidine | Destina | Detora | Dexio | Dictrin | Dinestin | Dingo | Disdine | Distamin | Doara | Dyl | Eslod | Eslor | Genelor | Histanil D | Jardin d | Kadisdin | Larinex | Lewdes | Lorades | Mdisin | Neo antial | Neolor | Neulorax | Retoret | Selora | Softin od | Weltol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Alerdes | Alergo max | AlergoTeva | Aleric deslo | Aleric deslo active | Azomyr | Clarderin | Dasergin | Dasselta | Dehistar | Delortan | Delortan allergy | Desada | Deslodyna | Desloratadine +pharma | Desloratadine actavis | Desloratadine aurovitas | Desloratadine dr.max | Desloratadine genoptim | Desloratadine mylan | Desloratadyna apotex | Dynid | Dynid gem | Flynise | Goldesin | Goldesin alerstop | Hitaxa | Hitaxa fast | Jovesto | Pylodes | Suprodeslon | Symdes | Teslor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Clarinex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Azomyr | Desloratadina actavis | Desloratadina alter | Desloratadina Aristo | Desloratadina aurobindo | Desloratadina aurovitas | Desloratadina azevedos | Desloratadina Basi | Desloratadina Bluepharma | Desloratadina ciclum | Desloratadina Cinfa | Desloratadina generis | Desloratadina krka | Desloratadina labesfal | Desloratadina mepha | Desloratadina Mylan | Desloratadina ratiopharm | Desloratadina teva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Alergicap | Desloradex | Despeval | Despex | Lomed | Loner | Mailen | Megadesaler fb | Neo alledryl | Recardex | Supraler</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aeriallerg | Aerius | Deslarex | Desloratadine/Genepharm | Desloren | Desrinal | Glendes | Histacare | Iris | Lorius | Rina</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Dasselta | Desloratadina actavis | Desloratadina alvogen | Desloratadina amring | Desloratadina aurobindo | Desloratadina Sandoz | Desloratadina terapia | Desloratadina teva | Dynid | Lordestin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Blogir 3 | Delorsin | Desal | Desloratadin | Desloratadine canon | Desloratadine Teva | Desloratadine vertex | Elizey | Eslontin | Ezlor | Lordestin | Nalorius</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Aeriallerg | Aerius | Deslin | Deslor | Desloratadine glenmark | Destamin | Dorius | Iris | Loradin | Loreta | Lorinex | Neorin | Rina</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Caredin | Dasselta | Desloratadin ABECE | Desloratadin Apofri | Desloratadin bijon | Desloratadin ebb | Desloratadin mylan | Desloratadin stada | Desloratadine actavis | Desloratadine glenmark | Desloratadine ratiopharm | Desloratadine sandoz | Desloratadine Teva | Flynise</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Alrinast | Desalex | Desloratadine sandoz</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Dasselta | Dasselta control | Desloratadin ratiopharm | Lentrica</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Azomyr | Dasselta | Dasseltino | Delesit | Deslomed | Desloratadin saneca | Desloratadin Zentiva | Desloratadine actavis | Desloratadine glenmark | Geslora | Jovesto | Lotera | Spirabel</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Desloratadine sandoz | Lorius</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Allergus | Clarius | Deslor | Desloryne | Histam | Lorinex</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Alores | Alrinast | Aria des | Deloday | Deslodin | Desloran | Desrinal | Dicomex | Doranit | Doxafin | Eslotin | Lordes</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Denosin | Desdin | Desora</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Alerdes | Alernova | Alersis | Allergomax | Allergostop | Astria | Blogir 3 | Desloratadine astrapharm | Desorus | Dezradin | Edem | Elehius | Elizium | Eridez darnitsa | Eslotin | Fribris | Hitaxa | Loratek | Lordes</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Alrinast | Deslora denk | Deslorat | Lorfact d | Neo loridin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Cripan | Delorat | Desloratadina Icu Vita | Desloratadina teva | Dislen | Mailen | Mailen rapid</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aerius | Bio Desloratadine | Desalex | Desler | Deslorat | Desloratadina | Deslorin | Deslort | Esparflin | Gamorvan | Histaler | Liberdux | Ofanex | Ventus</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Aleradin | Audocals | Bostanex | Bvpalin | Desdinta | Dessubaby | Elarothene | Eurodora | Ladexnin | Ruradin | Savoze | Sosallergy | Usdeslor</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Acuhist | Adco desloratadine | Aerius | Aerzit | Clarex | Dazit | Desaway | Deselex | Deseneeze | Desodene | Desotab | Loralex | Neoclarityne | Neoloridin | Pollentyme nd</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Aerius | D lor | Rodera</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Aerius (desloratadine) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; May 2019.</div>
</li>
<li>
<div class="reference">
                  Aerius (desloratadine) [prescribing information]. Haarlem, Netherlands: Merck Sharp &amp; Dohme; October 2018. https://www.ema.europa.eu/en/documents/product-information/aerius-epar-product-information_en.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/
                  </div>
</li>
<li>
<div class="reference">
                  Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed November 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24766875">
<a name="24766875"></a>Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. <i>J Allergy Clin Immunol</i>. 2014;133(5):1270-1277. doi:10.1016/j.jaci.2014.02.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/24766875/pubmed" id="24766875" target="_blank">24766875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28602936">
<a name="28602936"></a>Brożek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. <i>J Allergy Clin Immunol</i>. 2017;140(4):950-958.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/28602936/pubmed" id="28602936" target="_blank">28602936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.e1‐e427. doi:10.1016/j.jaad.2013.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17218934">
<a name="17218934"></a>Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. <i>MMWR Morb Mortal Wkly Rep</i>. 2007;56(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/17218934/pubmed" id="17218934" target="_blank">17218934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23456992">
<a name="23456992"></a>Cerminara C, El-Malhany N, Roberto D, Lo Castro A, Curatolo P. Seizures induced by desloratadine, a second-generation antihistamine: clinical observations. <i>Neuropediatrics</i>. 2013;44(4):222-224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/23456992/pubmed" id="23456992" target="_blank">23456992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24673465">
<a name="24673465"></a>Cicardi M, Aberer W, Banerji A, et al; HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. <i>Allergy</i>. 2014;69(5):602-616. doi:10.1111/all.12380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/24673465/pubmed" id="24673465" target="_blank">24673465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clarinex.1">
<a name="Clarinex.1"></a>Clarinex (desloratadine) [prescribing information]. Jersey City, NJ: Organon LLC; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Clarinex.1">
<a name="Clarinex.1"></a>Desloratadine orally disintegrating tablets [prescribing information]. Bachupally, India: Dr Reddy's Laboratories Limited; March 2019.</div>
</li>
<li>
<div class="reference">
                  Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. <i>Clin Pharmacokinet</i>. 2008;47(4):217-230. doi:10.2165/00003088-200847040-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/18336052/pubmed" id="18336052" target="_blank">18336052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29103802">
<a name="29103802"></a>Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. <i>Ann Allergy Asthma Immunol</i>. 2017;119(6):489-511.e41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/29103802/pubmed" id="29103802" target="_blank">29103802</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. <a href="https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm" target="_blank">https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference">
                  Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. <a href="https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm" target="_blank">https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm</a>. Last accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11295678">
<a name="11295678"></a>Geha RS, Meltzer EO. Desloratadine: A new, nonsedating, oral antihistamine. <i>J Allergy Clin Immunol</i>. 2001;107(4):751-762. doi: 10.1067/mai.2001.114239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/11295678/pubmed" id="11295678" target="_blank">11295678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17488362">
<a name="17488362"></a>Gupta S, Khalilieh S, Kantesaria B, Banfield C. Pharmacokinetics of desloratadine in children between 2 and 11 years of age. <i>Br J Clin Pharmacol</i>. 2007;63(5):534-540.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/17488362/pubmed" id="17488362" target="_blank">17488362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28081650">
<a name="28081650"></a>James C, Bernstein JA. Current and future therapies for the treatment of histamine-induced angioedema. <i>Expert Opin Pharmacother</i>. 2017;18(3):253-262. doi:10.1080/14656566.2017.1282461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/28081650/pubmed" id="28081650" target="_blank">28081650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khan.1">
<a name="Khan.1"></a>Khan DA. Chronic spontaneous urticaria: standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11398910">
<a name="11398910"></a>McClellan K, Jarvis B. Desloratadine. <i>Drugs</i>. 2001;61(6):789-796.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/11398910/pubmed" id="11398910" target="_blank">11398910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25711134">
<a name="25711134"></a>Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. <i>Clin Exp Allergy</i>. 2015;45(3):547-565.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/25711134/pubmed" id="25711134" target="_blank">25711134</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). <i>Clin Exp Allergy</i>. 2017;47(7):856-889.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25644617">
<a name="25644617"></a>Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(1 suppl):S1-S43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/25644617/pubmed" id="25644617" target="_blank">25644617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20226302">
<a name="20226302"></a>Staevska, M, Popov T, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. <i>J Allergy Clin Immunol</i>. 2010;125(3):676-682.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/20226302/pubmed" id="20226302" target="_blank">20226302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27372601">
<a name="27372601"></a>Trautmann A, Anders D, Stoevesandt J. H1-Antihistamine Premedication in NSAID-Associated Urticaria. <i>J Allergy Clin Immunol Pract</i>. 2016;4(6):1205-1212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/27372601/pubmed" id="27372601" target="_blank">27372601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29336054">
<a name="29336054"></a>Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy</i>. 2018;73(7):1393-1414.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/desloratadine-pediatric-drug-information/abstract-text/29336054/pubmed" id="29336054" target="_blank">29336054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zuraw.1">
<a name="Zuraw.1"></a>Zuraw B. An overview of angioedema: clinical features, diagnosis, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 29, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13211 Version 362.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
